Comparative Pharmacology
Head-to-head clinical analysis: NEXAVAR versus XALKORI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXAVAR versus XALKORI.
NEXAVAR vs XALKORI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Multikinase inhibitor targeting Raf, VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, Flt-3, and RET kinases, inhibiting tumor growth and angiogenesis.
Selective tyrosine kinase inhibitor targeting ALK, ROS1, and MET, inhibiting downstream signaling pathways (PI3K/AKT, MAPK/ERK) leading to reduced tumor cell proliferation and survival.
400 mg (two 200 mg tablets) orally twice daily approximately 12 hours apart on an empty stomach (at least 1 hour before or 2 hours after a meal).
250 mg orally twice daily.
None Documented
None Documented
Terminal half-life 25-48 hours; supports twice-daily dosing with steady state achieved in 7-14 days.
Terminal elimination half-life is approximately 72 hours (range 47-108 hours) in patients, supporting once-daily dosing.
Fecal (77% as unchanged drug and metabolites), renal (19% as metabolites, <1% as unchanged drug).
Primarily hepatic metabolism, with 53% of the dose recovered in feces (mostly as metabolites) and 22% in urine (1.1% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor